Reply to "Understanding the Assumptions on Anifrolumab Dose Regimen Selection for a Phase 3 Trial in Lupus Nephritis". (PubMed, Clin Pharmacol Ther) - Sep 26, 2026 - No abstract available
Journal • P3 data • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology
|
|
Catharina Lindholm; David Jayne; Joachim Almquist; Lynn Bertagnolli; Raj Tummala; Weifeng Tang; Yen Lin Chia
|